VIVUS (VVUS) Lower; Data Shows Unexpected Drop in Qsymia Prescriptions for Week 6 - BI

VIVUS, Inc. (Nasdaq: VVUS) is lower on the session following new prescription data for Qsymia in its sixth week.

Bloomberg Industries noted that prescriptions showed an "unexpected decline" for the week, falling 46 percent over the prior week. BI thinks this could be attributed to manufacturer-imposed blocking of data or some distributors not reporting.

BI noted that Source Healthcare Analytics affirmed the drop wasn't due to a change in data aggregation methodology.

Notably, growth showed some signs of slowdown last week, with Cowen taking a bearish stance on the potential for weight-loss pills, saying they were only appropriate for a niche market.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
• StubHub Holdings (STUB) PT Lowered to $12 at TD Cowen
• TD Cowen Reiterates Buy Rating on NVIDIA (NVDA), 'unlikely to move significantly on earnings'